Jon is a Partner at Forbion, based in Boston.
He focuses on sourcing, evaluating, and structuring new investments across company creation through early clinical development, working across therapeutic areas. His track record includes Excellergy (acquired by Novartis), Bicara Therapeutics (NASDAQ: BCAX), Impact Biomedicines (acquired by Celgene), Synthorx (acquired by Sanofi), Phathom Pharmaceuticals (NASDAQ: PHAT), and Checkmate Pharmaceuticals (acquired by Regeneron), among others.
Jon joined Forbion in 2025 and currently serves on the boards of Altesa, AiRNA, and Spoila. Prior to Forbion, he was a founding team member at Red Tree Venture Capital and Medicxi, and held roles at ClearView Healthcare Partners and Sepracor, Inc. Jon completed his postdoctoral research at MIT and holds a PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.
Portfolio
Companies worked on by Jon Edwards
